VYNE VYNE Therapeutics Inc
Price (delayed)
$1.64
Market cap
$24.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.93
Enterprise value
$5.12M
VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
Highlights
VYNE's debt has dropped by 54% year-on-year and by 20% since the previous quarter
VYNE's gross profit is up by 18% YoY
VYNE's EPS has shrunk by 128% QoQ but it has soared by 67% YoY
VYNE Therapeutics's quick ratio has shrunk by 66% YoY and by 25% QoQ
VYNE's equity is down by 41% year-on-year and by 18% since the previous quarter
Key stats
What are the main financial stats of VYNE
Market
Valuations
Earnings
Shares outstanding
15.21M
Market cap
$24.94M
Enterprise value
$5.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.46
Price to sales (P/S)
139.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.21
Revenue
$501,000
Gross profit
$501,000
Operating income
-$43.64M
Net income
-$39.83M
EBIT
-$39.83M
EBITDA
-$39.83M
Free cash flow
-$34.09M
Per share
Balance sheet
Liquidity
EPS
-$0.93
EPS diluted
-$0.93
Free cash flow per share
-$0.8
Book value per share
$3.53
Revenue per share
$0.01
TBVPS
$1.57
Total assets
$66.91M
Total liabilities
$14.82M
Debt
$99,000
Equity
$52.09M
Working capital
$49.62M
Debt to equity
0
Current ratio
4.35
Quick ratio
4.15
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
-7,949.3%
Gross margin
100%
Net margin
-7,950.9%
Operating margin
-8,710%
Return on assets
-49.6%
Return on equity
-58.2%
Return on invested capital
-83.5%
Return on capital employed
-76.5%
Return on sales
-7,950.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VYNE stock price
How has the VYNE Therapeutics stock price performed over time
Intraday
7.19%
1 week
-4.09%
1 month
-34.92%
1 year
-45.7%
YTD
-51.04%
QTD
3.8%
Financial performance
How have VYNE Therapeutics's revenue and profit performed over time
Revenue
$501,000
Gross profit
$501,000
Operating income
-$43.64M
Net income
-$39.83M
Gross margin
100%
Net margin
-7,950.9%
VYNE Therapeutics's operating income has decreased by 49% YoY and by 16% from the previous quarter
The net income has decreased by 40% YoY and by 17% from the previous quarter
VYNE's operating margin is down by 26% year-on-year and by 14% since the previous quarter
VYNE's gross profit is up by 18% YoY
Growth
What is VYNE Therapeutics's growth rate over time
Valuation
What is VYNE Therapeutics stock price valuation
P/E
N/A
P/B
0.46
P/S
139.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.21
VYNE's EPS has shrunk by 128% QoQ but it has soared by 67% YoY
VYNE's P/B is 73% below its 5-year quarterly average of 1.6 and 28% below its last 4 quarters average of 0.6
VYNE's equity is down by 41% year-on-year and by 18% since the previous quarter
VYNE's P/S is 84% above its 5-year quarterly average of 70.7 but 44% below its last 4 quarters average of 232.2
The revenue is up by 18% year-on-year
Efficiency
How efficient is VYNE Therapeutics business performance
VYNE's return on invested capital has surged by 62% year-on-year but it is down by 34% since the previous quarter
The ROE fell by 33% QoQ but it rose by 26% YoY
The ROA has contracted by 28% from the previous quarter but it has grown by 23% YoY
VYNE's ROS is down by 18% YoY and by 15% QoQ
Dividends
What is VYNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VYNE.
Financial health
How did VYNE Therapeutics financials performed over time
The current ratio has dropped by 66% year-on-year and by 25% since the previous quarter
VYNE Therapeutics's quick ratio has shrunk by 66% YoY and by 25% QoQ
VYNE's debt is 100% smaller than its equity
VYNE's debt has dropped by 54% year-on-year and by 20% since the previous quarter
VYNE's equity is down by 41% year-on-year and by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.